Form 4: Janux Therapeutics CEO Sells Shares Under 10b5-1 Trading Plan

Janux Therapeutics CEO, David Alan Campbell, sold a total of 25,000 shares of common stock on November 25, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• David Alan Campbell, the President and CEO of Janux Therapeutics, sold 18,281 shares of common stock at a weighted average price of $51.4322 per share on November 25, 2024.
• He also sold 6,719 shares of common stock at a weighted average price of $52.0385 per share on the same day.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on June 21, 2024.
• Following these sales, Mr. Campbell directly owns 257,054 shares of Janux Therapeutics common stock.

Sentiment

Score: 5

Explanation: The document is a routine disclosure of insider trading under a pre-arranged plan, which is neither positive nor negative in itself. It's a neutral event.

Risks

• Sales by company insiders can sometimes be perceived negatively by the market, potentially impacting the stock price.

Industry Context

The filing is a routine disclosure of insider trading activity, which is common for publicly traded companies. The use of a 10b5-1 trading plan is a standard practice to avoid accusations of trading on non-public information.

Comparison to Industry Standards

• The use of a 10b5-1 trading plan is a common practice among executives at publicly traded companies, including those in the biotechnology sector like Janux Therapeutics.
• Similar filings are regularly made by executives at companies like Amgen, Gilead Sciences, and Regeneron, when they execute pre-planned stock sales.
• The reported prices are within the expected range for the stock's trading activity.

Stakeholder Impact

• The stock sales may have a minor impact on shareholder sentiment, but the pre-planned nature of the transactions should mitigate any significant negative reaction.

Key Dates

Keywords

Janux Therapeutics, insider trading, Form 4, David Alan Campbell, 10b5-1 trading plan, stock sale, CEO